Fludarabine‐based cytoreductive regimen and T‐cell‐depleted grafts from alternative donors for the treatment of high‐risk patients with Fanconi anaemia
Sonali Chaudhury(Northwestern University), Farid Boulad(Memorial Sloan Kettering Cancer Center), Arleen D. Auerbach(Rockefeller University), Suzanne L. Wolden(Memorial Sloan Kettering Cancer Center), Nancy A. Kernan(Memorial Sloan Kettering Cancer Center), Andromachi Scaradavou(NewYork–Presbyterian Hospital), Richard J. O’Reilly(Memorial Sloan Kettering Cancer Center), Glenn Heller(Memorial Sloan Kettering Cancer Center), Trudy N. Small(Memorial Sloan Kettering Cancer Center), Susan E. Prockop(Memorial Sloan Kettering Cancer Center)
Cited by 82
Related Papers
Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program
|New England Journal of Medicine|1993|848
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience
|International Journal of Radiation Oncology*Biology*Physics|2005|421